Table 4 Clinical characteristics of five types of soft tissue sarcomas with a high risk of lymph node metastasis, before and after propensity score matching (PSM)
Variables | Lymph node treatment group in raw data | Lymph node treatment group after PSM | ||||
|---|---|---|---|---|---|---|
Non-NLND (n = 968) | NLND (n = 260) | P value | Non-NLND (n = 244) | NLND (n = 244) | P value | |
Age, median (IQR) | 46.0 [22.0;68.0] | 26.0 [12.0;47.2] | < 0.001 | 34.5 [13.0;57.2] | 29.0 [12.0;48.2] | 0.017 |
Age, years | < 0.001 | 0.703 | ||||
< 19 | 196 (20.2%) | 97 (37.3%) | 81 (33.2%) | 86 (35.2%) | ||
≥ 19 | 772 (79.8%) | 163 (62.7%) | 163 (66.8%) | 158 (64.8%) | ||
Race | 0.468 | 0.039 | ||||
White | 772 (79.8%) | 215 (82.7%) | 180 (73.8%) | 203 (83.2%) | ||
Black | 107 (11.1%) | 27 (10.4%) | 36 (14.8%) | 24 (9.84%) | ||
Other | 89 (9.19%) | 18 (6.92%) | 28 (11.5%) | 17 (6.97%) | ||
Sex | 0.173 | 0.069 | ||||
Female | 421 (43.5%) | 126 (48.5%) | 99 (40.6%) | 120 (49.2%) | ||
Male | 547 (56.5%) | 134 (51.5%) | 145 (59.4%) | 124 (50.8%) | ||
Year of diagnosis | 0.231 | 1 | ||||
1988–2005 | 364 (37.6%) | 109 (41.9%) | 105 (43.0%) | 105 (43.0%) | ||
2006–2015 | 604 (62.4%) | 151 (58.1%) | 139 (57.0%) | 139 (57.0%) | ||
Site | < 0.001 | 0.711 | ||||
Head, Face, Neck | 260 (26.9%) | 52 (20.0%) | 59 (24.2%) | 52 (21.3%) | ||
Upper limb, shoulder | 200 (20.7%) | 97 (37.3%) | 87 (35.7%) | 87 (35.7%) | ||
Lower limb, hip | 508 (52.5%) | 111 (42.7%) | 98 (40.2%) | 105 (43.0%) | ||
Grade | 0.127 | 0.899 | ||||
I + II | 114 (11.8%) | 25 (9.62%) | 22 (9.02%) | 25 (10.2%) | ||
III + IV | 408 (42.1%) | 97 (37.3%) | 94 (38.5%) | 93 (38.1%) | ||
Unknown | 446 (46.1%) | 138 (53.1%) | 128 (52.5%) | 126 (51.6%) | ||
Laterality | 0.022 | 0.9 | ||||
Left | 364 (37.6%) | 119 (45.8%) | 111 (45.5%) | 106 (43.4%) | ||
Right | 399 (41.2%) | 102 (39.2%) | 95 (38.9%) | 99 (40.6%) | ||
Unknown | 205 (21.2%) | 39 (15.0%) | 38 (15.6%) | 39 (16.0%) | ||
Histology | < 0.001 | 0.949 | ||||
Rhabdomyosarcoma | 255 (26.3%) | 78 (30.0%) | 73 (29.9%) | 78 (32.0%) | ||
Angiosarcoma | 344 (35.5%) | 42 (16.2%) | 44 (18.0%) | 42 (17.2%) | ||
Ewing sarcoma | 184 (19.0%) | 19 (7.31%) | 18 (7.38%) | 19 (7.79%) | ||
Epithelioid sarcoma | 109 (11.3%) | 75 (28.8%) | 69 (28.3%) | 62 (25.4%) | ||
Clear cell sarcoma | 76 (7.85%) | 46 (17.7%) | 40 (16.4%) | 43 (17.6%) | ||
Stage | 0.05 | 0.661 | ||||
Localized | 663 (68.5%) | 171 (65.8%) | 169 (69.3%) | 160 (65.6%) | ||
Regional | 238 (24.6%) | 79 (30.4%) | 65 (26.6%) | 74 (30.3%) | ||
Distant | 67 (6.92%) | 10 (3.85%) | 10 (4.10%) | 10 (4.10%) | ||
Size, cm | 0.006 | 0.597 | ||||
< 4 | 368 (38.0%) | 121 (46.5%) | 109 (44.7%) | 114 (46.7%) | ||
4–10 | 407 (42.0%) | 107 (41.2%) | 109 (44.7%) | 99 (40.6%) | ||
≥ 10 | 193 (19.9%) | 32 (12.3%) | 26 (10.7%) | 31 (12.7%) | ||
Marita status | < 0.001 | 0.858 | ||||
Married | 407 (42.0%) | 70 (26.9%) | 76 (31.1%) | 69 (28.3%) | ||
Never married | 404 (41.7%) | 152 (58.5%) | 134 (54.9%) | 139 (57.0%) | ||
Divorced/Widowed/Separated | 138 (14.3%) | 29 (11.2%) | 29 (11.9%) | 29 (11.9%) | ||
Unknown | 19 (1.96%) | 9 (3.46%) | 5 (2.05%) | 7 (2.87%) | ||
Survival months (median, IQR) | 47.0 [17.0;108] | 69.0 [26.8;136] | < 0.001 | 57.5 [21.0;120] | 69.5 [26.8;136] | 0.08 |